FDA notes Medtronic device deaths

Wall Street Journal (subscription required), March 20, 2008
The Food and Drug Administration said it saw a higher death rate after five years among patients treated for abdominal aortic aneurysms with Medtronic Inc.'s AneuRx stent-graft system than among those treated through conventional surgery. The FDA said it was focusing on the AneuRx stent-graft system because it is the only currently marketed device that has a significant number of patients who have been followed for at least five years after receiving a device.

MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2014 a division of BLR All rights reserved.